文献速递肝病

自动化低流量腹水泵治疗肝硬化患者难治性腹水

Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-09-21

本研究纳入德国、瑞士、英国和西班牙中心的56例有经颈静脉肝内门体分流术(TIPSS)禁忌证的难治性腹水肝硬化患者,随访至24个月,评估自动化低流量腹水泵(alfapump)的安全性和有效性。结果显示腹穿中位频率从每月2.17次降至0.17次,但17例因严重不良事件退出、23例死亡,48%患者泵系统被取出。结论认为alfapump可扩展治疗选择,但需技术改进以减少不良事件和再干预。

要点

  • 腹穿中位频率从每月2.17次降至0.17次。
  • 17例因严重不良事件退出,23例死亡,48%患者泵系统被取出。
  • 需技术和操作改进以减少不良事件和再干预。

核心结论

  • alfapump可扩展肝硬化难治性腹水患者的治疗选择。
  • 闭环自动化系统持续引流腹水使腹穿频率显著降低。
  • 需技术和操作改进以减少不良事件和再干预率。

研究设计与样本

  • 多中心研究,纳入德国、瑞士、英国和西班牙中心的56例患者(43例男性,平均年龄62岁),随访至24个月。
  • 评估有TIPSS禁忌证的难治性腹水患者接受alfapump治疗的安全性和有效性。
  • 记录并发症、装置缺陷、腹穿频率和患者生存。

主要发现

  • 分析时3例完成24个月观察期,3例监测中,9例接受肝移植,17例因严重不良事件退出,23例死亡。
  • 最常见技术并发症为腹膜导管阻塞。
  • 随访期间需23次泵相关再干预(17例患者)和12次泵更换(11例患者)。
  • 48%患者泵系统被取出(17例因严重不良事件,9例肝移植时,1例因难治性腹水恢复)。
  • 腹穿中位频率从每月2.17次降至0.17次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Refractory ascites (RA) is a frequent complication of cirrhosis, requiring large volume paracentesis or placement of a transjugular intrahepatic portosystemic shunt (TIPSS). The automated low-flow ascites pump (alfapump, Sequana Medical AG, Zurich, Switzerland) is an innovative treatment option for patients with RA. AIM: To assess safety and efficacy of this treatment in patients with a contraindication to TIPSS. METHODS: Fifty-six patients (43 males; mean age 62 years) from centres in Germany, Switzerland, UK and Spain were included and followed for up to 24 months. Complications, device deficiencies, paracentesis frequency and patient survival were recorded. RESULTS: At the time of this analysis, 3 patients completed the 24-month observation period, monitoring of 3 was ongoing, 9 underwent liver transplantation, 17 patients were withdrawn due to serious adverse events and 23 patients died. Most frequently observed technical complication was blocking of the peritoneal catheter. Twenty-three pump-related reinterventions (17 patients) and 12 pump exchanges (11 patients) were required during follow-up. The pump system was explanted in 48% of patients (in 17 patients due to serious adverse events, in 9 at the time of liver transplantation and in 1 due to recovery from RA). Median frequency of paracentesis dropped from 2.17 to 0.17 per month. CONCLUSIONS: The alfapump can expand therapeutic options for cirrhotic patients with RA. Continuous drainage of ascites in a closed loop automated system led to significant reduction in paracentesis frequency. Technical and procedural improvements are required to reduce the rate of adverse events and reinterventions. https://clinicaltrials.gov/ct2/show/NCT01532427.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stirnimann G, Berg T, Spahr L, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017. PMID: 28940225. doi:10.1111/apt.14331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。